SGLT2 Inhibitors and Finerenone: A friendly Duo in the Treatment of Diabetic Kidney Disease?

恩帕吉菲 盐皮质激素受体 医学 达帕格列嗪 肾功能 螺内酯 糖尿病 沙沙利汀 罗格列酮 肾脏疾病 内科学 2型糖尿病 泌尿科 重症监护医学 药理学 内分泌学 醛固酮 胰岛素 磷酸西他列汀
作者
Adlyne Reena Asirvatham,Arthur Asirvatham,Shriraam Mahadevan
出处
期刊:Journal of Association of Physicians of India [Association of Physicians of India]
卷期号:72 (12): e35-e41 被引量:3
标识
DOI:10.59556/japi.72.0759
摘要

For decades, achieving glycemic control, target blood pressure, and renin-angiotensin-aldosterone system (RAAS) blockade remained to be the therapeutic interventions for retarding diabetic kidney disease (DKD) progression. The management of DKD showed major transformation when SGLT2 inhibitors were recommended to reduce the risk of progressive deterioration in estimated glomerular filtration rate (eGFR), end-stage renal disease (ESRD), and renal death following results of CREDENCE and DAPA-CKD trials. Despite currently available therapeutic approaches, the risk of cardiac death, progression to ESRD, and requirement of renal replacement therapy remains high. Finerenone is the newer potent selective nonsteroidal mineralocorticoid receptor antagonist (MRA) that showed reduction in primary composite renal and CV outcomes in FIDELIO-DKD and FIGARO-DKD studies, respectively. While SGLT2 inhibitors have direct effects on cellular and metabolic functions besides reduction in glomerular hyperfiltration, finerenone primarily inhibits mineralocorticoid pathway-dependent inflammation and fibrosis. The renal benefits of dapagliflozin in the DAPA-CKD trial were regardless of MRA, and likewise, the benefits of finerenone in FIDELIO and FIGARO studies were irrespective of SGLT2i. Moreover, the risk of serious hyperkalemia with MRA was significantly reduced by concomitant use of SGLT2 inhibitors, making this combination a safer choice. Even though available data support the fact that this duo possibly has distinct as well as complementary mechanisms in protecting renal and cardiac functions, strong evidence to recommend routine use of the combination of SGLT2 inhibitors and MRA in DKD is currently lacking. However, the results of the ongoing CONFIDENCE study evaluating superiority of dual therapy of empagliflozin and finerenone will be worthwhile to understand the benefits of this friendly duo.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
JamesPei的应助被ZhuJing采纳,获得10
1秒前
丁真爱抽锐克五完成签到,获得积分20
2秒前
XX完成签到,获得积分10
2秒前
2秒前
生动友容完成签到,获得积分10
3秒前
霜降完成签到,获得积分10
6秒前
wuweizhizhi完成签到,获得积分10
6秒前
陈住气完成签到,获得积分10
6秒前
沐沐完成签到,获得积分10
6秒前
Ava的应助被木木采纳,获得10
8秒前
听一万遍枫完成签到,获得积分10
8秒前
9秒前
科研通AI6.3的应助被myh采纳,获得10
9秒前
vebb完成签到,获得积分10
10秒前
顾矜的应助被黄毛虎采纳,获得10
11秒前
帅气鸭子完成签到 ,获得积分10
11秒前
12秒前
香蕉觅云的应助被Vincent采纳,获得10
13秒前
光风霁月完成签到 ,获得积分10
13秒前
momo完成签到,获得积分10
14秒前
坚强孤容发布了新的文献求助10
14秒前
14秒前
misscloud关注了科研通微信公众号
15秒前
orixero的应助被三羊开泰采纳,获得10
16秒前
Doro完成签到,获得积分10
16秒前
16秒前
5EN完成签到,获得积分10
17秒前
17秒前
2001完成签到,获得积分10
18秒前
kunkun发布了新的文献求助10
18秒前
19秒前
沫茶发布了新的文献求助10
19秒前
阿南发布了新的文献求助10
20秒前
青青发布了新的文献求助10
22秒前
木木发布了新的文献求助10
23秒前
23秒前
顾矜的应助被ZhuJing采纳,获得30
23秒前
詹慧子发布了新的文献求助10
23秒前
23秒前
玛卡巴卡完成签到,获得积分10
24秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186898
求助须知:如何正确求助?哪些是违规求助? 9575232
关于积分的说明 21840305
捐赠科研通 7784667
什么是DOI,文献DOI怎么找? 3434891
关于科研通互助平台的介绍 2559294
邀请新用户注册赠送积分活动 2481741